Search results
Results from the WOW.Com Content Network
Formula: C 7 H 8 N 4 O 2: Molar mass: 180.167 g·mol −1: ... Theophylline is metabolized extensively in the liver. [2] ... and by the early 1980s in a tablet form ...
Symptoms include vague abdominal pain, nausea, abdominal fullness, malaise and weight loss. They may also include a palpable liver mass. [14] Other presentations include jaundice, ascites, fulminant liver failure, encephalopathy, gynecomastia (males only), thrombophlebitis of the lower limbs, recurrent deep vein thrombosis, anemia and hypoglycemia.
Trinitrotoluene spin view. Trinitrotoluene (/ ˌ t r aɪ ˌ n aɪ t r oʊ ˈ t ɒ lj u iː n /), [5] [6] more commonly known as TNT (and more specifically 2,4,6-trinitrotoluene, and by its preferred IUPAC name 2-methyl-1,3,5-trinitrobenzene), [1] is a chemical compound with the formula C 6 H 2 (NO 2) 3 CH 3.
N-Phenylacetyl-l-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cyclic glycine-proline. [a] [2] Other names include the brand name Noopept (Russian: Ноопепт), developmental code GVS-111, and proposed INN omberacetam.
Reaction catalyzed by lactate dehydrogenase. Lactate dehydrogenase catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD +.It converts pyruvate, the final product of glycolysis, to lactate when oxygen is absent or in short supply, and it performs the reverse reaction during the Cori cycle in the liver.
Liver biopsy is the biopsy (removal of a small sample of tissue) from the liver. It is a medical test that is done to aid diagnosis of liver disease , to assess the severity of known liver disease, and to monitor the progress of treatment.
[5] [4] With long-term use, the adverse effects of high-dose nicotinic acid therapy (750 mg per day) also include liver failure (associated with fatigue, nausea, and loss of appetite), hepatitis, and acute liver failure; [5] [4] these hepatotoxic effects of nicotinic acid occur more often when extended-release dosage forms are used.
In March 2021, in a phase III randomized, double-blind trial, 1,961 adults with a body mass index of 30 or greater were assigned in a 2:1 ratio to a treatment with once-weekly subcutaneous semaglutide or placebo, plus lifestyle intervention. The trials occurred at 129 sites in 16 countries in Asia, Europe, North America, and South America.